Evidence mapPaperPMID 41789657Full record

ArticleOncology reports2026

Cellular and inflammatory characteristics of patient‑derived glioblastoma organoids during

Jessica Nojszewski, Nils Oliver Schröder, Jacqueline Clüver, Jonna Holler, Hajrullah Ahmeti, Michael Synowitz, Janka Held-Feindt

Abstract read
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jessica Nojszewski *Department of Neurosurgery, University Medical Center Schleswig‑Holstein (UKSH), Campus Kiel, D‑24105 Kiel, Germany.
Nils Oliver Schröder *Department of Neurosurgery, University Medical Center Schleswig‑Holstein (UKSH), Campus Kiel, D‑24105 Kiel, Germany.
Jacqueline ClüverDepartment of Neurosurgery, University Medical Center Schleswig‑Holstein (UKSH), Campus Kiel, D‑24105 Kiel, Germany.
Jonna HollerDepartment of Neurosurgery, University Medical Center Schleswig‑Holstein (UKSH), Campus Kiel, D‑24105 Kiel, Germany.
Hajrullah AhmetiDepartment of Neurosurgery, University Medical Center Schleswig‑Holstein (UKSH), Campus Kiel, D‑24105 Kiel, Germany.
Michael SynowitzDepartment of Neurosurgery, University Medical Center Schleswig‑Holstein (UKSH), Campus Kiel, D‑24105 Kiel, Germany.
Janka Held-FeindtDepartment of Neurosurgery, University Medical Center Schleswig‑Holstein (UKSH), Campus Kiel, D‑24105 Kiel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastomas are characterized by extensive intra‑ and intertumoral heterogeneity, which drives their rapid invasive growth and frequent recurrence. As a result, prognosis remains poor, and developing effective treatments continues to be a major challenge. The survival and growth of glioblastomas are supported by a specific, protective tumor microenvironment (TME) that influences tumor morphology, growth rate, therapy resistance and recurrence. To better represent the complex TME with its immune cells and inflammatory mediators and the tumor heterogeneity, including glioma stem‑like cells (GSCs), realistic

Indexed as

Brain NeoplasmsGlioblastomaOrganoidsAgedBiomarkers, TumorCell Culture TechniquesCell ProliferationCytokinesFemaleHumansMaleMiddle AgedNeoplastic Stem CellsTumor MicroenvironmentBiomarkers, TumorCytokinesglioblastomalong‑term cultivationorganoidstumor heterogeneitytumor microenvironmenttumoroids

Identifiers

PMID41789657
PMCPMC12980305

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.